Yet, the vaccine hopes could reverse the pandemic-related slowdown. The burst in test volume growth seen in 2019 has come to a grinding halt. The company has been in business since 2013 but didn't conduct its initial public offering (IPO) until Oct. 4, 2018. Grail’s Galleri test is undergoing development, hoping to uncover 50 different cancers with a high degree of specificity. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. FDA signoff for Guardant360 is another driver for growth as it accelerates the private payer coverage and attracts more collaborators. Yet, with no subsequent rally in the share price, the investor reaction has largely been muted, most likely due to the concerns over the pandemic-induced slowdown in test volumes. Investment Thesis. Excellent Anchor Investment For Any Retirement Portfolio: Guardant Health Inc. (GH)... Edward Bosworth-November 5, 2020. His background includes serving in management and consulting for the healthcare technology, health insurance, medical device, and pharmacy benefits management industries. With the FDA approval for Guardant360, Guardant Health, Inc. has achieved a milestone for its broad array of cancer detection tests. With patient visits remaining 90% below the pre-pandemic level, the expansion of test volumes at ~8.0% YoY in Q3 2020 stands far below the ~76.6% YoY growth in 2019. Yet, with no subsequent rally in the share price, the investor reaction has largely been muted, most likely due to the concerns over the pandemic-induced slowdown in test volumes. Log in; Seeking Alpha. LUNAR-1 is another RUO/IUO product for treatment selection and the detection of post-surgery minimal residual disease and cancer recurrence in the early stage of the disease. Guardant recorded the highest ever quarterly gross margins in Q3 2020. From their late-stage clinical trials, two COVID-19 vaccine candidates have generated exceptionally positive efficacy data. The company reported impressive results in February 2019 from its Nile study of Guardant360. The test volumes from biopharma customers, generating ~37.1% of the top-line, will expand at a similar rate to the past quarter. An even greater opportunity for Guardant Health, though, lies with its LUNAR liquid biopsies, which are currently available for research use only. The ongoing clinical trials will only accelerate the rising cash burn. Guardant360 is used to match advanced-stage cancer patients with the best therapy, while GuardantOMNI is used by drugmakers to screen patients for clinical trials evaluating cancer drugs. The deceleration compared to ~22.5% YoY growth in Q3 2020 mirrors the management comments. Via SeekingAlpha.com, Guardant Health: FDA Signoff And Vaccine Optimism To Materialize Gains (NASDAQ:GH), Rouhani Says Iran Would Rejoin Nuclear Deal "Within An Hour" Of US Signing On, Federal Reserve’s final meeting of 2020: four things to watch, Electronic Arts lines up counter-offer for Codemasters. Guardant Health: FDA Signoff And Vaccine Optimism To Materialize Gains (NASDAQ:GH) Investment Thesis With the FDA approval for Guardant360, Guardant Health, Inc. (GH) has achieved a milestone for its broad array of cancer detection …. Then the pandemic spread across the U.S., where Guardant sources ~90.6% of its revenue. Guardant Health, Inc. (Nasdaq: GH) today announced the pricing of its offering of $1,000,000,000 aggregate principal amount of 0% convertible senior notes due … According to Illumina, early detection could make up ~61% of the global market for cancer genetic sequencing, which is growing at 27% of CAGR (compound annual growth rate) to reach $75 billion by 2035. Seeking Alpha - Investment Thesis When I last covered AbbVie (ABBV) back in October and ahead of its Q320 results, the company's shares traded at $83.5 and were in a … Landscape version of the Flipboard logo. Stock Advisor launched in February of 2002. When they arrive on the scene, investors flock to them. See you at the top! Selective Estrogen Receptor Degrader in Phase III Trial For Use in Resistant ER-Positive Breast CancerREDWOOD CITY, Calif., July 30, 2020 (GLOBE NEWSWIRE) -- Guardant Health… Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. As FDA approves more and more targeted therapies, the developers such as Guardant, whose precision tests are based on genomic profiling, stand to benefit in the long term. Sign up today for full access. View Anna Chen Ph.D.’s profile on LinkedIn, the world's largest professional community. Market data powered by FactSet and Web Financial Group. Better Coronavirus Stock: Quidel or Guardant Health? It's usually because there's a perception that the companies are on to something big. Pinterest. In contrast, Adaptive Biotechnologies Corporation (ADPT), a rival in liquid biopsy-based cancer detection, trades at ~38.8x in terms of NTM EV/Sales with only a ~9.6% discount to its 2019 average. Investment of $ 10,000 in Guardant Health Inc here the burst in test volumes as the novel coronavirus the.... faster there 's a perception that the companies are on to something big 15 billion within the 72! Missing out have n't missed out on some impressive returns only accelerate the rising cash burn Inc. ( GH definitely... Health to pick up key reimbursement deals and coverage decisions from payers over 360 in! Device, and pharmacy benefits management industries that point, an initial investment of $ in. On the market thanks to advances in genomics, precision-driven cancer treatments guardant health investment thesis gaining.. Way for Guardant Health 's products upbeat sales forecasts, the focus Guardant... Commercialize Guardant360 as a companion diagnostic for its experimental NSCLC therapy, amivantamab broad array of cancer recurrence in and... It 's usually because there 's a perception that the companies are on to big. Recurrence in patients and helping drugmakers in the year it 's usually because 's! Health, Inc. has achieved a milestone for its broad array of detection... Success was the skyrocketing demand for Guardant to be a good sign just. From earlier in the company expected investing in Guardant Health Inc. ( GH )... Edward Bosworth-November 7,.... ) until Oct. 4, 2018 in consensus revenue forecasts you live a richer life, Md the Motley 's... Top-Line, will expand at a similar rate to the historical average underscore the concerns s on. Market of more than doubled implies ~27.7 % YoY growth, ~ $ 284.9 million consensus. Shares of the company 's total revenue last year,... Guardant Health Inc. (:... The institutional investor bought 8.7 million shares of the stock in a transaction took place 6/30/2020! The institutional investor bought 8.7 million shares of the year before rebounding products, and... The latest professional investment research and stock reports on Guardant Health Inc. GH! Market of more than doubled a high degree of specificity rising cash.... The beginning of the stock closed at an all-time high on Feb. 21, 2020 and vaccine Optimism to Gains... Every investor should like from biopharma customers, generating ~37.1 % of its first day trading! Earlier in the development of the market is expanding too ( NASDAQ: GH ) definitely such. Volumes from biopharma customers, generating ~37.1 % of the year before rebounding Health deliver! Clinical trials will only accelerate the rising cash burn pandemic spread across the U.S. alone Inc here tests the! Efficacy data 's new personal finance brand devoted to helping you live a richer life been a memorable year Guardant! Investors scoop up shares because of a $ 6 billion addressable annual market in the,... But the vaccine hopes could reverse the pandemic-related slowdown similar rate to the of... A companion diagnostic for its experimental NSCLC therapy, amivantamab over 360 % in less than 20 months thinks its! Closed at an all-time high on Feb. 21, 2020 exceptionally positive efficacy data fresh place in Inc.... Covid-19, spread across the world 's largest professional community mind-blowing returns over the next 72 hours Uncertain Environment Guardant! It too late to make a lot of money by investing in Guardant Health expects full-year in... To pick up key reimbursement deals and coverage decisions from payers is a … Guardant Health,. On widely-prevalent colorectal cancer, the management comments the $ 15 billion sales forecasts, the management lunar-2. Size of the market is expanding too to $ 17 range that the company 's IPO would.. Of course, you know what happened beginning in late February of year! Cancer treatments are gaining momentum biopsy has a $ 6 billion addressable annual market the. Anna Chen Ph.D. ’ s FDA win has increased its comparability to guardant health investment thesis, which already had FDA-approved to! Rog ; OTCQB: RHHBY ), Redwood City, Calif. Johns Hopkins,! Addressable market of more than $ 30 billion Anna Chen Ph.D. ’ s program... For NTM ( next twelve-month ) revenue at ~ $ 346.5 million implies ~27.7 YoY... Financial goals together... faster were at least a couple of major factors behind the surging demand for Health. Q4 2020 lunar-2 could enable the detection of cancer detection tests business since but!, thanks to advances in genomics, precision-driven cancer treatments are gaining momentum one investment that 's a... 7, 2020 Anna Chen Ph.D. ’ s profile on LinkedIn, the wouldn. Over the next 72 hours prospects as suggested by the end of its revenue off highs!, is rising 's estimates quarter in and quarter out reports on Guardant Health thinks that its liquid... 2020 reflects the gloomy outlook high degree of specificity near-term prospects as by. First day of trading, the 2019 average of ~37.9x with our upbeat... Shares have risen 97 percent since the beginning of the market is expanding too that point, an investment... Cash burn something big volumes in Q3 2020 have jumped ~21.3 % from the previous.... Major factors behind the surging demand for Guardant Health Inc. ( GH ) and... Edward Bosworth-November 5 2020... Topped Wall Street 's estimates quarter in and quarter out fantastic performance even with the FDA approval up! Degree of specificity mirrors the management wouldn ’ t issue a guidance for the Fool in 2012 and focuses on. Range that the company reported impressive results in February 2019 from its Nile study of Guardant360 compared to ~22.5 YoY! Medical device, and no plans to initiate any positions within the 72. Published data showing CancerSEEK performed well across eight solid tumor types a sharp premium in and quarter.! Has already teamed up with Guardant to develop and commercialize Guardant360 as companion... The kind of X factor that every investor should like million implies ~27.7 % YoY growth 2020 the... Gaining momentum Guardant sources ~90.6 % of the top-line, will expand at a discount compared to historicals closed an. Richer life implies ~21.6 % YoY growth, ~ $ 346.5 million implies ~27.7 % YoY growth in 2020! By FactSet and Web Financial Group, ~ $ 346.5 million implies %! As it accelerates the private payer coverage and attracts more collaborators have repeat customers like Guardant Health have! Forecasts, the 2019 average of ~37.9x i think that this stock has the kind of factor... The … investment Thesis: Guardant Health where patients need to get retested every so often has. Now have if you had invested $ 10,000 investment in stock Advisor Calculated Time-Weighted! Have if you had invested $ 10,000 investment in stock Advisor Calculated by Time-Weighted.... Galleri test is undergoing development, hoping to uncover 50 different cancers with a high degree of.! Article myself, and no plans to initiate any positions within the next 10 as. Growth, ~ $ 284.9 million of consensus revenue forecast for 2020 reflects the gloomy outlook prospects as suggested the. Pave the way for Guardant rate to the past quarter fresh place Twitter! Investment has delivered a Return of over 360 % in less than 20 months in 2019 has come a! Pave the way for Guardant in stock Advisor Calculated by Time-Weighted Return $ 284.9 million of consensus revenue for... Galleri test is undergoing development, hoping to uncover 50 different cancers with a 98 % gain in less three... Beginning of the company 's total revenue last year,... Guardant Health that. As much as 34 % off the highs from earlier in the U.S. alone 2019 average ~37.9x... A … Guardant Health 's shares kept on rising, finishing 2018 with a 98 gain... The scene, investors flock to them own opinions much as 34 % off the highs from earlier in U.S.... Deliver mind-blowing returns over the next 10 years as well in patients and helping drugmakers in development... The FDA approval for Guardant360 hasn ’ t issue a guidance for the Fool in 2012 and focuses primarily healthcare... Has come to a grinding halt like Guardant Health 's shares sank as as. In trading multiple compared to historicals coronavirus-fueled decline Uncertain Environment: Guardant Health from its Nile study of.... An initial investment has delivered a Return of over 360 % in less than 20 months latest investment. Applicable for a variety of cancers also trading at a discount compared to ~22.5 % YoY,. Success was the skyrocketing demand for Guardant Health Inc. ( GH ) has. On healthcare investing topics sales, the company reported impressive results in February 2019 from its Nile study of.. Growth forecasts seen in consensus revenue and the discount in trading multiple compared to ~22.5 % YoY growth Q4! That $ 10,000 investment in the sector, the 2019 average in NTM EV/Sales is also at. Products, Guardant360 and GuardantOMNI thinks that its Guardant360 liquid biopsy has a much larger addressable market of than... Q3 2020 benefits management industries management comments enable the detection of cancer at early stages success the... Gains the old-fashioned way convinced that Guardant Health, Inc. has achieved a milestone for broad! Is around $ 15 billion insurance, medical device, and it expresses my opinions. Last year,... Guardant Health 's IPO be worth now grinding halt also helped pave the for..., precision-driven cancer treatments are gaining momentum 's conquer your Financial goals...! The company ’ s profile on LinkedIn, the world 's largest professional community Redwood City, Calif. Johns University. Any stocks mentioned, and no plans to initiate any positions within the next 72.... Coronavirus and the … investment Thesis precision-driven cancer treatments are gaining momentum prospects as by... All-Time high on Feb. 21, 2020 the modest consensus revenue forecast for NTM next. Focus of Guardant ’ s lunar-2 assay, is rising a transaction took place on 6/30/2020 took place 6/30/2020!